Bull case
ImageneBio is attractive because IMG-007 sits in a clinically validated OX40/OX40L pathway for atopic dermatitis and alopecia areata, where meaningful unmet need remains despite approved biologics and JAK inhibitors that are constrained by safety and efficacy limitations. Its non-depleting design, ~5-week half-life, and lack of reported pyrexia, chills, ulcers, hypersensitivity, or infusion reactions in more than 150 treated patients support a differentiated safety and dosing profile, while early efficacy was compelling with an 87% mean EASI reduction through Week 20 and a 21.7% SALT reduction at Week 36 in severe AA. The company’s single-asset opportunity is further de-risked by competitor validation and could become financially meaningful, with projected risk-adjusted revenue of $529M in 2037 for AD, $338M in 2037 for AA, and first risk-adjusted full-year product revenues of about $205M in 2033 growing to $867M in 2037.